Reify Health, Inc.

Based in Massachusetts, US, and founded in 2015 by co-founders Henry Li, Joseph Abrahamson, Michael Lin, Pramod Verma, and Ralph Passarella, Reify Health, Inc. operates as a developer of a cloud-based healthcare software designed to help shorten clinical trial timelines. The company's system software is used by biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across more than 100 countries. In August 2021, the company raised USD 220 million in Series C funding led by Coatue Management, with participation from ICONIQ Growth and Adams Street Partners, Sierra Ventures, and Battery Ventures.

The series C funding values Reify Health, Inc. at USD 2. 2 billion post-money. Reify Health's StudyTeam is a cloud-based software system that accelerates enrollment timelines and the overall pace of research, enabling research sponsors, clinical research sites, and coordinators to obtain the insight.

The company's StudyTeam platform optimizes patient recruitment and enrollment and the CareAccess research organization brings clinical trial infrastructure directly to patients, healthcare providers, and communities. Reify Health plans to expand its business entities, CareAccess and StudyTeam. CareAccess plans to accelerate its global operations and foster partnerships with clinics and other healthcare organizations. The StudyTeam platform to continue to scale and expand its functionality to enable stakeholders in decentralized trials in executing the complex logistics required to bring trials to patients.